[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362448-105":59,"doc-detail-362448-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unlocking-the-promise-of-innate-biology-through-the-hla-gilt2ilt4-pathway","Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway","","Inhibitory immune pathways have gained attention following cancer successes of immune checkpoint inhibitors. While classical checkpoints like PD-1/PD-L1 and CTLA-4 dominate focus, alternative immunosuppressive mechanisms drive immune evasion, tumor progression, and therapy resistance. This review centers on the HLA-G/ILT2/ILT4 axis as an immunosuppressive pathway promoting immune escape. It engages NK cells, myeloid cells, and antigen-experienced T cells via mechanisms and tumor profiles largely distinct from PD-L1 and CTLA-4. Early clinical work exists, yet evidence remains limited due to constraints such as small cohorts and PD-1 combination bias, motivating further refinement and patient selection.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unlocking-the-promise-of-innate-biology-through-the-hla-gilt2ilt4-pathway/362448/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unlocking-the-promise-of-innate-biology-through-the-hla-gilt2ilt4-pathway/362448.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why focus on the HLA-G/ILT2/ILT4 pathway in cancer immunotherapy?","Question",{"text":112,"@type":113},"Because HLA-G and its receptors ILT2 and ILT4 regulate antitumor responses through an immunosuppressive axis that promotes immune escape. The review emphasizes that its effects and tumor expression profiles are largely non-overlapping with PD-L1 and CTLA-4.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the HLA-G/ILT2/ILT4 axis differ from classical immune checkpoints like PD-1/PD-L1 and CTLA-4?",{"text":117,"@type":113},"The review highlights distinguishing features of this pathway, including unique engagement of NK cells, myeloid cells, and antigen-experienced T cells. It also notes that its immune effects and tumor profiles are largely distinct from PD-L1 and CTLA-4.",{"name":119,"@type":110,"acceptedAnswer":120},"What limitations have affected assessment of therapeutic efficacy in early clinical studies?",{"text":121,"@type":113},"The review points to small sample sizes, heavily pretreated patient populations, and an emphasis on PD-1 combinations in patients experienced with PD-1/PD-L1 inhibitors. These constraints have limited a clear evaluation of the axis’ therapeutic potential.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362448,1790212041,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Open access Review  \n Unlocking the promise of innate  \nbiology through the HLA-G/ILT2/ ILT4 pathway  \nCourtney Beers  ,1 Robert L Ilaria,1 Jason J Luke2  \nTo cite: Beers C, Ilaria RL, Luke JJ. Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway. Journal for ImmunoTherapy of Cancer 2026;14:e013313 . doi:10.1136/jitc-2025-013313  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013313](jitc-2025-013313)) .  \nAccepted 27 January 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Tizona Therapeutics Inc, South San Francisco, California, USA 2UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA  \nCorrespondence to  \nDr Courtney Beers; [cbeers@tizonatx.com](cbeers@tizonatx.com)  \nABSTRACT  \nInhibitory immune pathways have gained considerable attention following the clinical success of immune checkpoint inhibitors in cancer. While much focus has been placed on classical checkpoints such as programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), alternative immunosuppressive mechanisms are increasingly recognized as contributors to immune evasion, tumor progression, and therapeutic resistance. Among these, non-classical human leukocyte antigens (HLAs), particularly HLA-G and its receptors ILT2 and ILT4, have emerged as key players regulating antitumor responses.  \nThis review highlights the HLA-G/ILT2/ILT4 axis as a distinct immunosuppressive pathway within the HLA family promoting immune escape. This pathway engages natural killer (NK) cells, myeloid cells, and antigen-experienced T cells through unique mechanisms and is characterized by effects on immune cell subsets and tumor expression profiles that are largely non-overlapping with PD-L1 and CTLA-4. These distinguishing features underscore its potential as a novel and promising pathway to expand the scope of immune checkpoint-based interventions.  \nAlthough early-phase clinical studies have begun to explore this axis, robust evidence of therapeutic efficacy remains limited. Constraints such as small sample sizes, heavily pretreated patient populations, and an emphasis on PD-1 combinations in PD-1/PD-L1 inhibitor-experienced patients may have hindered a clear assessment of its potential. Nonetheless, the unique biology of this pathway supports its potential as a novel target for cancer therapeutics. Continued research is needed to refine tumor subtypes, identify responsive patient subsets, and clarify their therapeutic relevance.  \nINTRODUCTION  \nWhile cancer immunotherapy has transformed clinical outcomes, many patients with solid tumor cancer experience limited benefit from programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) blockade. Numerous additional immunoregulatory receptors contribute to shaping immune responses within the tumor microenvironment, including the commonly expressed HLA-G/ILT2/ILT4 pathway. In  \nthis review, we outline the fundamental biology supporting this axis and the rationale for its therapeutic targeting. We then summarize current clinical efforts and discuss opportunities and next steps for advancing HLA-G/ ILT2/ILT4-directed therapies, including identifying specific patient populations and combinations with mechanisms beyond PD-1/PD-L1 inhibition.1  \nBACKGROUND  \nNon-classical MHC class 1  \nThe human leukocyte antigen (HLA) system includes both classical (HLA-A, HLA-B, HLA-C) and non-classical (HLA-E, HLA-F, HLA-G, HLA-H) major histocompatibility complex (MHC) class I molecules. MHC class I molecules are cell surface resident type 1 transmembrane glycoproteins that possess a common molecular architecture with an α 1 and an ","cbCaikg8WUVSIWms","https://ap.wps.com/l/cbCaikg8WUVSIWms","pdf",1962063,12,"English","# Abstract\n# Introduction\n# Background\n## Non-classical MHC class 1\n## HLA-G","[{\"question\":\"Why focus on the HLA-G/ILT2/ILT4 pathway in cancer immunotherapy?\",\"answer\":\"Because HLA-G and its receptors ILT2 and ILT4 regulate antitumor responses through an immunosuppressive axis that promotes immune escape. The review emphasizes that its effects and tumor expression profiles are largely non-overlapping with PD-L1 and CTLA-4.\"},{\"question\":\"How does the HLA-G/ILT2/ILT4 axis differ from classical immune checkpoints like PD-1/PD-L1 and CTLA-4?\",\"answer\":\"The review highlights distinguishing features of this pathway, including unique engagement of NK cells, myeloid cells, and antigen-experienced T cells. It also notes that its immune effects and tumor profiles are largely distinct from PD-L1 and CTLA-4.\"},{\"question\":\"What limitations have affected assessment of therapeutic efficacy in early clinical studies?\",\"answer\":\"The review points to small sample sizes, heavily pretreated patient populations, and an emphasis on PD-1 combinations in patients experienced with PD-1/PD-L1 inhibitors. These constraints have limited a clear evaluation of the axis’ therapeutic potential.\"}]","Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway | PDF",1790147789,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a080377bddc022584a723f96e75768f.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d4a551975010c18cfa9b339556e32f6.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59d99c3b7828d725ba8defd2ea058922.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/648122578d6d541f7bb341794fb97a37.webp",980,1306]